Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Exenatide on Hypothalamic Obesity.

Trial Profile

Effects of Exenatide on Hypothalamic Obesity.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use

Most Recent Events

  • 24 Sep 2019 Status changed from active, no longer recruiting to completed.
  • 30 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
  • 22 Feb 2016 According to ClinicalTrials.gov record, the primary endpoint has been amended.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top